



# aidence

human sense in artificial intelligence

CE certified second or concurrent reader,  
suitable for routine clinical practice and  
lung cancer screening

Among the first AI medical devices to  
comply with the new EU Medical  
Device Regulation (MDR)

FDA 510(k) clearance pending


## Veye Lung Nodules

The one-click AI assistant for  
pulmonary nodule management

Making a radiology assessment is much more than finding abnormalities on scans. Yet when reporting chest CT scans for lung nodules, you spend most of your time searching for millimetric lesions with the naked eye, counting, segmenting, and measuring them (semi-)manually.

Pulmonary nodule reporting should not add to your already high workload or force you to make follow-up decisions in which you are not fully confident.

Veye Lung Nodules is ready to assist you with all the time-consuming, tedious and error-prone tasks. **Automatically.**



## Automated lung nodule management on chest CT scans

- **Detection:** solid & sub-solid nodules, 3-30mm
- **Classification:** solid or sub-solid composition
- **Quantification:** diameters, volume, size filter
- **Growth assessment:** growth percentage & volume doubling time

## Integrated into your workflow

Veye Lung Nodules runs in the background, automatically processing all eligible studies, including the most recent prior, if available. Its results are delivered **directly to the PACS**, as part of the original diagnostic series. The results are available to anyone with PACS access, **on or off-site. Or from home. Anytime.**

When you start reading the scan, Veye Lung Nodules' analysis is already present - there is **no need for extra clicks**, log-ins, and waiting time. Your workflow stays the same - while your reading is supported by powerful AI technology.

## Validated performance



The clinical performance of Veye Lung Nodules has been validated in a study performed by the University of Edinburgh and NHS Lothian. On default settings, Veye detects nodules at a **sensitivity of 91%** at the cost of 1 false positive on average per scan.

The performance has been **confirmed by independent research** published in *Clinical Radiology* (volume 76, issue 11).

Results from a clinical study with two radiologists show an average **~ 40% reduction in reading time** when reporting on pulmonary nodules with Veye. The findings have been published in *European Journal of Radiology Open* (volume 9).



## Proven value for patients


Volumetric analysis offers better insight into the evolution of a nodule than diameter. It is recommended as the **gold standard** by the British Thoracic Society. However, performing volume measurements manually is cumbersome and time-consuming.

Veye Lung Nodules solves the problem by providing **automated volumetry**.


In a case reported by a Dutch hospital, a nodule's change in diameter seemed minor; thus, the radiologist was inclined not to follow up. Running in the background, Veye Lung Nodules correctly identified a significant volume growth.

The nodule proved to be malignant. With Veye's help, the lung cancer patient received a **timely diagnosis**.

### Volume



### Diameter



**Growth: 90% | VDT: 89 days**

## Trusted across Europe

Veye Lung Nodules has been validated at scale in clinical practice. It is currently running in **over 60 hospitals** across Europe, analysing thousands of patient scans each week.

In the UK, it is the AI solution of choice in the **NHS England's Targeted Lung Health Checks**, a nationwide lung cancer screening initiative. It is also the subject of a study into the clinical impact of AI on radiology decision-making.

**The Netherlands Cancer Institute**, one of the world's top 10 comprehensive cancer centers, is using Veye Lung Nodules in their cancer clinic.

Veye has been handpicked by **AstraZeneca** for the European PINPOINT project, aiming to increase early lung cancer diagnosis through better detection and follow-up of incidental pulmonary nodules.

Regardless of your hospital's location, the Aidence service team offers dedicated, **local training and support**.

### We are Aidence

Driven by the purpose of giving cancer patients a fighting chance.  
Part of RadNet's AI Division

Get in touch to learn more or schedule a demo: [www.aidence.com](http://www.aidence.com)



## Loved by users

"Simple, yet effective."

**Dr. Caroline McCann**,  
Liverpool Heart and Chest Hospital (UK)

"Like having a high-quality trainee review each and every scan before you do."

**Dr. James Shambrook**,  
University Hospital Southampton (UK)

"It allows us to read scans at a high pace with the confidence of not missing anything."

**Dr. Paul Algra & Dr. Floris Rietema**,  
Northwest Clinics (NL)

"This is just what our radiologists need."

**Dr. Oliver Byass**,  
Hull University Teaching Hospitals (UK)